Tambocor is a brand-name medication that contains the active ingredient flecainide. Flecainide belongs to the class IC anti-arrhythmic drugs and is used to treat certain abnormal heart rhythms. In Hong Kong, Tambocor is available only by prescription and is supplied as an oral pill in two strengths: 50 mg and 100 mg. The medication is regulated by the Hong Kong Department of Health, which follows standards similar to those of the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Flecainide works by blocking fast-acting sodium channels in cardiac cells. By reducing the influx of sodium during the early phase of the cardiac electrical impulse, the drug:
These actions help restore a normal rhythm in patients with supraventricular tachycardia (SVT) or certain ventricular arrhythmias. The drug is rapidly absorbed after oral administration, reaching peak blood levels within 1-3 hours. It is metabolized mainly by the liver and excreted unchanged in the urine.
Tambocor is approved for the following indications, consistent with regulatory labeling in Hong Kong and internationally:
These uses are based on clinical trials that demonstrated flecainide’s ability to convert or maintain sinus rhythm and to suppress recurrent ventricular episodes.
These reactions are usually transient and may improve with dose titration.
A black-box warning accompanies flecainide labeling to highlight the risk of life-threatening arrhythmias in unsuitable patients.
Mechanism: many interactions involve inhibition of hepatic metabolism (CYP2D6) or additive electrophysiological effects on cardiac conduction.
If you are taking other prescription medicines, over-the-counter drugs, or herbal supplements, inform your healthcare provider before starting Tambocor.
This article provides educational information about Tambocor and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Combining flecainide with other Class I anti-arrhythmics (e.g., quinidine, propafenone) can increase the risk of serious conduction disturbances. Such combinations should only be used under strict specialist supervision with continuous ECG monitoring.
After oral ingestion, flecainide reaches peak blood concentrations within 1-3 hours. Patients often notice a reduction in arrhythmic episodes within the first few days, but full therapeutic effect may require several weeks of steady dosing.
Flecainide primarily influences heart rhythm rather than blood pressure. However, in some individuals it may cause mild hypotension, especially when combined with beta-blockers or calcium-channel blockers.
Yes, but keep the medication in its original labeled container, carry a copy of the prescription, and be aware of Hong Kong’s customs rules for controlled medicines. Short-term travel does not usually require additional documentation.
Visual symptoms such as blurred vision or photophobia can be an early sign of flecainide toxicity. Contact your healthcare provider promptly; dose adjustment or further evaluation may be necessary.
Mild hepatic impairment (Child-Pugh A) generally permits standard dosing, but many clinicians start at a lower dose (e.g., 50 mg once daily) and monitor liver function tests and ECG closely.
Grapefruit juice can modestly inhibit CYP2D6, the enzyme that metabolizes flecainide, potentially raising drug levels. It is advisable to limit grapefruit consumption while taking Tambocor.
Certain herbal products like St. John’s Wort induce CYP enzymes and may lower flecainide concentrations, reducing efficacy. Always discuss any supplements with your pharmacist or physician.
Signs of excessive dosing include persistent dizziness, significant visual changes, severe fatigue, or new arrhythmic episodes. If any of these occur, seek medical advice promptly for possible dose reduction.
Tambocor (flecainide) is a Class IC sodium-channel blocker with a relatively short half-life and a narrow therapeutic window. Amiodarone is a Class III potassium-channel blocker with a very long half-life and a broader safety profile, but it carries distinct organ-specific toxicities (e.g., thyroid, pulmonary). Choice of agent depends on the specific arrhythmia, patient comorbidities, and physician expertise.
